Skip to content
          • Log In
      Drug Discovery World (DDW)Drug Discovery World (DDW)
        • About Us
        • Subscribe Free
        • Media Info
        • Contact Us
          Drug Discovery World (DDW) Menu   ≡ ╳
          • Home
          • News
          • Exclusive Content
            • Features
            • Opinion
            • Market Reports
            • Trends & Analysis
            • Start-up Zone
          • DDW eBooks & eReports
          • Cancer Research
          • Business
          • Regulatory
          • Events
          • Webinars
          • Resources
          • Magazine
            • Digital Issues
            • Archive
          • Multimedia
            • Videos
            • Podcasts

        • Sidebar Banner 6

        • Sidebar Banner 7

        • Sidebar Banner 8

        • Sidebar Banner 12

        • Sidebar Banner 18

        • Sidebar Banner 19

        • Sidebar Banner 20

        • Sidebar Banner 21

        1. Home
        2. Sickle cell disorder (SCD)

        Sickle cell disorder (SCD)

        CRISPR gene editing

        Great Britain first to approve CRISPR-based gene therapy

        16 November 2023

        The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the world’s first gene therapy for sickle-cell disease (SCD) and transfusion-dependent β-thalassemia (TDT). Casgevy (exagamglogene autotemcel, or exa-cel) is the first medicine to be licensed that uses gene editing tool CRISPR, for which its inventors were awarded the Nobel Prize in 2020. The treatment from […]

        This week in drug discovery (11-15 July)

        15 July 2022

        News round-up by DDW’s Reece Armstrong for 11 – 15 July. Urgency a must for global fight against AMR, report says Urgent access to vaccines that can fight and prevent infections, and curb the risk of antimicrobial resistance (AMR) is needed to save lives, according to a report by the World Health Organisation (WHO). Could […]

        First treatment for sickle cell side-effect in 20 years approved

        13 July 2022

        The first new treatment in 20 years that prevents a common, painful side-effect in patients with sickle cell disorder (SCD) has been issued interim acceptance by the Scottish Medicines Consortium (SMC).  The SMC issued interim acceptance for Novartis UK’s Adakveo for use in NHS Scotland as a treatment option for the prevention of recurrent vaso-occlusive […]

        Sidebar Banner 1

        Sidebar Banner 2

        Sidebar Banner 3

        Sidebar Banner 4

        Sidebar Banner 9

        Sidebar Banner 10

        Sidebar Banner 11

        Sidebar Banner 13

        Sidebar Banner 14

        Sidebar Banner 15

        Sidebar Banner 16

        Sidebar Banner 17

          • Contact Us
          • About Us
          • Subscribe FREE
          • Media Info
          • Log In
          • Terms and Conditions
          • Privacy Policy
          • Cookie Policy

        Follow our social accounts

             

        Copyright 2023 © Drug Discovery World (DDW). All Rights Reserved

        Designed & Developed with ❤ for digital by Inbound FinTech

        • Home
        • News
        • Exclusive Content
          • Features
          • Market Reports
          • Opinion
          • Trends & Analysis
          • Start-up Zone
        • DDW eBooks & eReports
        • Cancer Research
        • Business
        • Regulatory
        • Events
        • Webinars
        • Resources
        • Magazine
          • Digital Issues
          • Archive
        • Multimedia
          • Podcasts
          • Videos
        • About Us
        • Subscribe Free
        • Media Info
        • Contact Us
            • Log In